
Compass Pathways completed its NDA for COMP360 based on 2 phase 3 trials and a phase 2b study with more than 1000 participants with highly chronic TRD.
Paul Ruberg, PA-C, presents a patient case and discusses the importance of educating patients and about the treatment process.